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I N T R O D U C T I O N  
Multiple factors have been shown to influence the pharmacokinetics, pharma- 
codynamics and, hence, dosage requirements of the oral anticoagulant, warfarin (1-3). 
The relationship between patient age in the adult population and warfarin mainten- 
ance dose is controversial. Several studies (4-6) have found a significant inverse 
correlation between age and dose, and it has been reported (5) that the elderly, when 
compared to a population of relatively younger adults, are more sensitive to the 
pharmacologic effects of the drug at any given dose. Subsequently, two other research 
groups (7,8), however, failed to conrim a significant age-dose relationship. 
A recent study by Dobrzanski et al. (9) found both an inverse correlation between 
age and warfarin maintenance dose ( r =  -0.39; P <  0.01) and a positive correlation 
between patient total body weight and warfarin dosage requirements ( r  = 0.39; 
P < 0.01). Although the authors acknowledged that additional variables affect warfarin 
dose, they suggested that patient age and weight may be a useful guide in choosing 
initial warfarin maintenance doses. I t  is presently uncommon in clinical practice for 
warfarin dose to be calculated on the basis of weight (i.e. mg/kg), and the only other 
study in the literature which reported the relationship between weight and dose (6) 
failed to find a significant correlation between those parameters. 
If a relationship between patient weight and warfarin dose exists, the correlation 
may be greater if lean body weight (i.e., the lesser of either total body weight minus 
excess weight due to obesity or, in the case of a lean individual, actual body weight) 
were utilized instead of total body weight. Such a finding would be expected since 
warfarin has a low volume of distribution consistent with its high affinity for serum 
proteins. It partitions poorly into adipose tissue and, therefore, the apparent volume of 
distribution should not increase linearly with total body weight in the case of an obese 
patient (1). For the same reasons, a relatively strong correlation between lean body 
weight-derived body surface area (BSA) and dosage requirements should be found. 
The  objectives of our study were, therefore, to attempt to verify the findings of 
Dobrzanski and coworkers, and to determine if measures of lean body weight and BSA 
will enhance the predictive value of the potential correlation between body weight and 
warfarin maintenance dose. 
*Correspondence: Dr D. M. Kirking, College of Pharmacy, University of Michigan, Ann Arbor, 
Michigan, U. S.A., 48 109-1 065. 
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M E T H O D O L O G Y  
Prescription records were used to identify all patients being monitored for mainten- 
ance warfarin therapy at a Veterans Administration Medical Center. The  majority of 
patients identified were followed by a pharmacist-managed anticoagulation surveil- 
lance clinic. Patients who had been on therapy for less than 3 months were excluded to 
allow for stabilization of dosing requirements. Because of the nature of the hospital, 
all 95 study patients were males. The  goal of therapy was to maintain patients a t  a 
prothrombin time (PT) of between 1.5 and 2.5 times control, and preferably between 
1.5 and 2.0 times control, since more aggressive oral anticoagulant therapy has been 
shown to increase the risk of bleeding complications but has not been proven to 
enhance therapeutic effect (10, 11). Prothrombin times were performed using a photo- 
optical sensor with fibrin clot formation as the endpoint. The  reagent used was rabbit 
brain thromboplastin from Ortho Diagnostics, New Jersey, U.S.A. 
Because some variability of dose requirements over time is likely even in a ‘well- 
controlled patient’, a mean warfarin dose and mean P T  value were calculated for each 
patient by averaging the values recorded at each visit or for the most recent 2-year 
period, in the case of long-term therapy. An average of 12.9 warfarin determinations 
per patient was obtained. Unlike Dobrzanski et  al., who evaluated only those patients 
whose prothrombin times fell within a P T  ratio range of between two or three as 
estimated using Manchester reagent, our results were determined for all patients as 
well as for the subsample of patients whose mean PT was within our therapeutic range. 
Pearson product-moment correlation coefficients were determined for mean warfarin 
maintenance dose and for the following parameters: age, actual body weight, lean body 
weight, actual BSA and lean body weight-derived BSA. T h e  correlation analyses were 
conducted for both the entire sample and for the ‘therapeutic’ subsample. 
The  following formulae were used for lean body weight and body surface area 
calculations, respectively: 
LBW (kg)=51.7 kg+ 1.85 kg/inch over 5 feet 
(or actual body weight, whichever was less) 
BSA (mZ) = weight (kg)O 425 x height (cm)o 725 x 7 1.84 (13). 
R E S U L T S  A N D  D I S C U S S I O N  
Mean values of patient characteristics for our overall sample (n=95)  and the sub- 
sample of patients within the therapeutic range of P T  (?1=82) (the ‘therapeutic 
subsample’) are presented in Table 1. For the overall sample, a significant inverse 
correlation was found between mean maintenance dose and age ( r  = - 0.32, P = 0,001), 
but not between mean maintenance dose and total body weight ( r  =0.10). No signifi- 
cant correlation was found between dose and either lean body weight, actual BSA, or 
lean weight-derived BSA ( r  = 0.17, 0.08 and 0.07, respectively). Similar correlation 
coefficients were found for the relationships between dose and age, actual body weight, 
lean body weight, actual BSA and lean weight-derived BSA for the therapeutic sub- 
sample ( r =  -0.35 [ P = O . O O l ] ,  0.12, 0.20, 0.10 and 0.09, respectively). As expected 
from these correlations, multiple regressions of age and any of the various body weight 
and body surface area factors on warfarin dose did not add significantly to the 
predictive value of age alone. 
Warfarin dose and age, weight and body surface area 
Table 1. Patient characteristics' 
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Parameter Overall sample? Therapeutic subsample: 
Age (years) 56.2 _+ 10.3 55.9 * 10.2 
Body surface area 2.0 _+ 0.2 2-0 f 0.2 
83-5 f 19.8 
69.1 f 6.6 
Actual body weight (kg) 
Lean body weight (kg)$ 68.8 6.3 
83.3 _+ 19.1 
(BSA) (m') 
BSA (m') 
Warfarin dose (mg) 
Mean prothrombin ratio 
Lean body weight-derived 1.8 1 . 1  1.8_+1.1 
6.9 f 3.0 6 9 f 3.0 
1.73 k0.15 1.72 f 0.24 
'Values are means _+ SD. 
tAll  patients identified who met study inclusion criteria, regardless of 
:Subsample of overall sample whose mean PT ratio was within the 
$Lean body weight for each patient was determined as the lesser of either 
mean P T  ratio (n = 95). 
therapeutic range of 1.5-2.5 times control ( n  = 82). 
the patient's ideal body weight or actual body weight. 
These findings confirm the previously reported (4, 5,9)  correlation between age and 
warfarin dose. We were unable, however, to corroborate the existence of the weight- 
warfarin dose relationship reported by Dobrzanski er al. even with the use of an 
enhanced method to estimate warfarin maintenance dose and more pharmacokineti- 
cally sound means of expressing body weight (i.e., lean body weight and lean weight- 
derived body surface area). Reasons for the differences in findings between the two 
studies are not clear. It is unlikely that the weight-dose relationship reported by 
Dobrzanski and his colleagues was a byproduct of an age-dose correlation, since they 
did not h d  a significant correlation between the age and weight of their patients. 
Another difference that was noted between the two studies was that the mean 
warfarin dose for both our overall patient sample and the subsample of patients with 
a therapeutic PT ratio was substantially higher than that reported by Dobrzanski 
(6.89 mg versus 4.24 mg, respectively). This difference may, in part, be due to inter- 
study variations in the thromboplastin reagent utilized and in the defined therapeutic 
P T  ratio ranges (14, 15). It is difficult to compare PT ratios quantitatively between 
different institutions and studies (15). However, a therapeutic range of 1.5-2.0 times 
control (rather than 1.5-2.5 times control) using our rabbit brain thromboplastin 
reagent would more closely approximate the therapeutic range utilized in the 
Dobrzanski study (2.0-3.0 times control using Manchester reagent) (15). Of the 82 
patients in our therapeutic subpopulation (i.e., those that have a mean P T  ratio of 
1.5-2.5 times control using rabbit thromboplastin), 76 had PT ratios of less than 2.0 
(mean of 1.71 kO.12). Yet, the mean warfarin dose required to attain that more con- 
servative degree of anticoagulant control for this subgroup was still 6.9 k 3.0 mg. It is, 
therefore, unlikely that the 63",, interstudy difference in mean doses is predominantly 
related to variation in thromboplastin reagent and/or defined therapeutic range. 
Additional factors are likely to contribute to this dissimilarity. 
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Although the mean age of the population of Dobrzanski and coworkers was slightly 
greater than the current study (59.2 years & 10.9 and 56.2 yearsf 10.3), this slight 
difference is unlikely to account for the relatively large dissimilarity in dose. One 
difference between the two study populations was that our study was conducted using 
only males while the other population was presumably comprised of both men and 
women, although no breakdown of study subjects by gender appears within the 
Dobrzanski data. It has been reported that women tend to be more prone to warfarin- 
related bleeding complications and that their dosage requirements tend to be lower 
than those of the male population (2, 16). These reports, however, fail to cite the 
source of this information and O'Malley ef QI. (4) found that gender did not affect anti- 
coagulant control. If women are, indeed, more sensitive to the pharmacologic effects of 
the drug, the apparent difference between the studies in mean warfarin dose required 
to attain a therapeutic PT ratio might be related to differences in gender composition 
between the snidies. Other potential dissimilarities in the study populations, such as 
differences in the incidence of liver dysfunction, uraemia, and smoking also have the 
ability to influence certain study results. 
Consideration of patient age, but not patient weight, appears valid when choosing 
an initial warfarin maintenance dose. However, many additional factors, including 
hepatic function, diet, and even gender also appear to contribute to variations in 
warfarin requirements. There is a significant potential for harm when administering 
the wrong dose of warfarin, and relative difficulty is often experienced in ident- 
ifying the most appropriate initial maintenance dose. Further research to identify 
determinants of warfarin dose and to de-ielop dosing guidelines based upon multiple 
regression should be encouraged. 
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